RESUMEN
The major role of liver glycogen is to supply glucose to the circulation maintaining the normal blood glucose level. In muscle and liver the accumulation and breakdown of glycogen are regulated by the reciprocal activities of glycogen phosphorylase and glycogen synthase. Glycogen phosphorylase catalyses the key step of glycogen degradation and its activity can be inhibited by glucose and its analogues. Obviously, any readily accessible inhibitor of glycogen phosphorylase can be used as a potential therapy of non-insulin-dependent or type 2 diabetes. Hepatic glycogen phosphorylase has been identified as a new target for drugs that control blood glucose concentration. In our experiments glucopyranosylidene-spirothiohydantoin (TH) was tested on the insulin sensitivity and blood glucose level of control and streptozotocin-treated rats. The streptozotocin-treated rats failed to gain weight and exhibited stable hyperglycemia (4.7 ± 0.5 mmol/L glucose in control vs. 7.8 ± 0.5 mmol/L) and low plasma insulin levels (9.6 ± 1.9 µIU/mL in control vs. 3.2 ± 2.2 µIU/mL). When insulin supplementation with slow-release implants (2 IU/day) was started 8 weeks after streptozotocin injection, blood glucose concentration remained suppressed, plasma insulin level dramatically increased and the insulin sensitivity restored. TH administration significantly reduced the high blood glucose concentration and restored the insulin sensitivity of STZtreated rats.
Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Glucógeno Fosforilasa/antagonistas & inhibidores , Hipoglucemiantes/uso terapéutico , Resistencia a la Insulina , Insulina/sangre , Monosacáridos/uso terapéutico , Compuestos de Espiro/uso terapéutico , Animales , Glucemia/análisis , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/enzimología , Glucógeno/metabolismo , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Insulina/uso terapéutico , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Monosacáridos/administración & dosificación , Ratas Wistar , Compuestos de Espiro/administración & dosificación , EstreptozocinaRESUMEN
The major role of liver glycogen is to supply glucose to the circulation in order to maintain normal blood glucose levels. In the muscle and liver, the accumulation and breakdown of glycogen are regulated by the reciprocal activities of glycogen phosphorylase and glycogen synthase. Glycogen phosphorylase catalyses the key step of glycogen degradation and its activity is inhibited by glucose and its analogues. Thus, any readily accessible inhibitor of glycogen phosphorylase may serve as a potential therapy for non-insulin-dependent or type 2 diabetes. Hepatic glycogen phosphorylase has been identified as a novel target for drugs that control blood glucose concentration. Glucopyranosylidene-spiro-thiohydantoin (TH) was found to be one of the most potent glucose derivates, inhibiting the catalytic activity of both muscle and liver glycogen phosphorylase. Here, we demonstrated the co-ordinated regulation of glycogen phosphorylase and synthase by 50 µM TH in liver extracts of Wistar rats, resulting in the activation of synthase by a shortening of the latency compared to control animals. TH was also effective in lowering blood glucose levels and restoring hepatic glycogen content in streptozotocin-induced diabetic rats. Furthermore, intravenous administration of TH to Zucker diabetic fatty rats significantly decreased hepatic glycogen phosphorylase a levels, and the activation of synthase was initiated without any delay.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Glucógeno/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Monosacáridos/farmacología , Obesidad/metabolismo , Compuestos de Espiro/farmacología , Animales , Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/complicaciones , Activación Enzimática/efectos de los fármacos , Glucógeno Fosforilasa/metabolismo , Glucógeno Sintasa/metabolismo , Inyecciones Intravenosas , Hígado/enzimología , Masculino , Monosacáridos/administración & dosificación , Obesidad/sangre , Obesidad/complicaciones , Fosforilación/efectos de los fármacos , Ratas , Ratas Wistar , Ratas Zucker , Compuestos de Espiro/administración & dosificaciónRESUMEN
Preparation of O-peracetylated N-beta-d-glucopyranosyl-N'-acyl urea derivatives resulted in the formation of anomeric mixtures under the following conditions: acylation of O-peracetylated beta-d-glucopyranosyl urea by acyl chlorides in the presence of ZnCl(2) in refluxing CHCl(3); addition of O-peracetylated beta-d-glucopyranosylamine to acyl isocyanates in acetonitrile at rt; addition of carboxamides to in situ prepared O-peracetylated beta-d-glucopyranosyl isocyanate in refluxing toluene. Deprotection of O-peracetylated N-beta-d-glucopyranosyl-N'-acyl ureas either under base (NaOMe in MeOH at or below rt) or under acid (KHSO(4) or AcCl in MeOH at rt) catalyzed transesterification conditions resulted in unavoidable partial cleavage of the N'-acyl moieties. Reaction of beta-d-glucopyranosylammonium carbamate with an isocyanate, isothiocyanate or isoselenocyanate in dry pyridine at rt appears as a general method for the preparation of the corresponding beta-d-glucopyranosyl ureas, -thio- and -selenoureas, respectively, inclusive N'-acyl derivatives.